Tumor necrosis factor alpha gene polymorphism and association with its serum level in Iranian population with rheumatoid arthritis.
In human, the TNF-[alpha] gene is located on the short arm of chromosome 6 in the 6P21 region where the class III region of the human leukocyte antigen genes is located. (13) Several single nucleotide polymorphisms (SNP) have been demonstrated in the promoter region of the TNF-[alpha] gene and some of them are known to affect the level of gene expression. (14) Of these, mutation in the promoter region with a G [right arrow] A substitution in position -238 (rs361525G/A), has been the subject of intense studies. (15-17) A study showed that -238 allele is associated with higher TNF-[alpha] production with respect to the -238 G allele, (18) however, this result was not confirmed by other studies. (19,20) The G [right arrow] A substitution in position -238 in the TNF-[alpha] gene is associated with lower production of TNF-[alpha] in patients with ulcerative colitis. (21)
To the best of our knowledge, no studies have investigated the potential association between -238 G/A TNF-[alpha] gene polymorphism with RA in Iranian population. Therefore, in this study, we aimed to determine whether promoter -238 G/A polymorphism in TNF-[alpha] gene is associated with susceptibility to RA in Iranian population and serum level of TNF-[alpha].
PATIENTS AND METHODS
This case-controlled study was performed between March 2012 and December 2013 on two groups including 90 RA patients (20 males, 70 females; mean age 50.3 years; range 26 to 65 years) who referred to the Rheumatology Clinic of Shahid Sadoughi hospital, Yazd, Iran and 90 healthy controls (21 males, 69 females; mean age 48.6 years; range 27 to 63 years) who were randomly selected from the general population who lived in the same area, strictly unrelated, and without history of chronic inflammatory or autoimmune disease. The subjects fulfilled the 2010 American College of Rheumatology-European League Against Rheumatism classification criteria for RA. (22) Disease activity was assessed using the Disease Activity Score 28 (DAS28). Subjects in both groups were matched in terms of age and sex. All patients were examined by a rheumatologist. The Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran approved the study design. Signed informed consent was obtained from each subject. The study was conducted in accordance with the principles of the Declaration of Helsinki.
A sample of peripheral venous blood (10 mL) was taken from all participants. Five milliliters of each blood sample were collected in ethylenediaminetetraacetic acid coated tubes for deoxyribonucleic acid (DNA) extraction and the rest centrifuged after clotting and the serum harvested and stored in -70[degrees]C until used. In the RA group, hemoglobin level was measured by an automated cell counter (CelltacE, Nihon Kohden, Japan). The Westergren method was used to determine the erythrocyte sedimentation rate at the laboratory.
The RF and C-reactive protein (CRP) levels in all sera were measured by standard kit according to manufacturer's instructions (Pishtaz Teb and Bionic Company, Iran respectively) and using auto analyzer (Prestige 24i, Japan).
Serum concentration of Anti-CCP in the RA group was determined by enzyme-linked immunosorbent assay method according to the manufacturer's instructions (AESKU. Diagnostics GmbH & Co. KG, Wendelsheim, Germany).
The levels of TNF-[alpha] in the RA and control groups were measured by enzyme-linked immunosorbent assay method according to the kit instructions (eBioscience, Bender Med Systems, GmbH, Austria). The sensitivity of TNF-[alpha] kit was 1.65 Pg/mL.
Genomic DNA was extracted from peripheral blood using a DNA extraction kit (Bioneer, Daejeon, Korea) according to the manufacturer's instructions. Determining of -238 G/A TNF-[alpha] was performed using polymerase chain reaction (PCR) restriction fragment length polymorphism method. PCR reaction was carried out in 25 [micro]L reaction volumes containing 100 ng of genomic DNA, 1.5 mM MgCl2, 0.2 mM dNTP, 10 pmol of each primer and 1 unit of Taq DNA polymerase. PCR reagents were purchased from the CinnaGen Company (Tehran, Iran). Primers were designed according to published sequences in the Genome Database (GenBank) using the software PRIMER3. Information on primer sequences is as follows:
Forward: 5'-AGAAGACCCCCCTCGGACTC-3', Reverse: 5'-GCTGGTCCTCTGCTGTCCTT-3'
The PCR cycling conditions were as follows: five minutes at 94[degrees]C, 30 cycles of denaturation for one minute at 94[degrees]C, annealing for one minute at 61[degrees]C and extension for one minute at 72[degrees]C. A final extension time of five minutes at 72[degrees]C was included at the end of last cycle (Applied Biosystems, ABI, Foster City, CA, USA). The product size of PCR was 315 base pairs (bp) that was confirmed by electrophoresis in a 1% agarose gel stained with the DNA green viewer (Pars-Tous, Iran). The PCR product was digested by an addition restriction enzyme Ddel (Promega, USA, Cat No. R6295) at 37[degrees]C for 60 minutes in a final volume of 20 [micro]L under the following conditions; 10 [micro]L PCR product, 7.3 [micro]L deionized water, 2 [micro]L 10x buffer, 0.5 pL Ddel and 0.2 pL acetylated bovine serum albumin. The resulting fragments of the restriction fragment length polymorphism were analyzed using electrophoresis on 2% gel agarose. All the gels were imaged using E-gel imager (Life Technologies) instrument. Ten samples from each group were randomly selected to perform the repeated assays, and the results were 100% concordant.
The statistical analyses were performed with the SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). SNP were evaluated for deviation from Hardy-Weinberg Equilibrium for both RA and control groups by a Chi-square test. The genotype and allele frequencies of -238 G/A polymorphism were calculated by direct count. Chi-square test was used to evaluate the differences between the genotype frequency in the RA and control groups. The mean of serum TNF-[alpha] between RA and control groups and comparison mean serum concentrations of TNF-[alpha] in the RA and control groups in the genotypes GG, GA and AA were analyzed with Mann-Whitney U test. In RA group, Spearman's correlation test was used to test the correlation between the mean serum TNF-[alpha] level and anti-CCP, RF, and CRP. The data for serum TNF-[alpha] are shown as mean [+ or -] standard error of mean and for the others as mean [+ or -] standard deviation. P-values less than 0.05 were considered statistically significant.
All participants of the study (90 RA patients and 90 controls) were genotyped for the -238G/A TNF-[alpha] gene polymorphism. The TNF-[alpha] genotype frequencies were in Hardy-Weinberg Equilibrium in two groups (p>0.05). Demographic and clinical characteristics of subjects are summarized in
Table 1. There was no significant difference between the groups in terms of sex and age. Levels of RF were significantly different between the groups (p<0.001). Also, RA patients had a significantly higher level of CRP than the controls (p<0.001). Serum level of TNF-[alpha] was 5.21 [+ or -] 1.69 Pg/mL (range 0 to 11.6) in the control group and 62.4 [+ or -] 27.1 Pg/mL (range 0 to 117.22) in the RA group. RA patients showed significantly increased serum TNF-[alpha] level as compared to controls (p<0.0001). In the RA group, there was no correlation between TNF-[alpha] .serum concentration and serum levels of anti-CCP (r=0.05, p=0.5), RF (r=0.09, p=0.3), and CRP (r=0.12, p=0.2).
The product size was 315 bp for SNP -238 G/A (Figure 1). There were three bands (262, 24 and 13 bp) in the presence of homozygous AA and two bands (275 and 24 bp) in the presence of homozygous GG after enzymatic digestion by Ddel. GG genotype was the most frequent allele in RA (76.6%) and control groups (83.5%). There was no significant difference in the genotype frequencies of the -238 G/A polymorphism between both groups (p=0.07). Also, G allele was the dominant allele in both the RA (85.5%) and control (87.2%) groups. The allele frequencies of the -238 G/A polymorphism between two groups were similar (p=0.1). The data are shown in Table 2. The mean serum levels of TNF-[alpha] in RA patients with different genotypes of -238 G/A were compared. Our results showed that no significant differences in serum TNF-[alpha] levels and different genotypes (p=0.5). Mean of DAS28 in GG, GA, and AA genotypes were 3.3 [+ or -] 0.9, 3.1 [+ or -] 0.6, and 4.5 [+ or -] 1.1, respectively. AA genotype showed a statistically significant higher DAS28 than GG and GA genotypes (p=0.01).
Cytokines are important mediators of the immune system and imbalance or deficiency in the cytokine network may lead to autoimmunity disease susceptibility. TNF-[alpha] is a multifunctional, proinflammatory cytokine, which plays an important role in many autoimmune diseases. The TNF-[alpha] gene has been postulated as a key genetic factor in inflammatory and autoimmune diseases. (23) The gene is tightly regulated at the level of transcription. (24,25) In this study, we compared the serum level of TNF-[alpha] in RA patients and healthy controls. Our results showed that RA patients had a significantly higher level of TNF-[alpha] than controls. TNF-[alpha] has an important role in the regulation of a cascade of pathogenesis events leading to RA. This cytokine is produced in high concentration by a number of cells, such as monocyte and T cells in RA. (26) The pivotal role of TNF-[alpha] in pathogenesis of RA has been demonstrated in successful clinical trials targeting TNF-[alpha] and in collagen-induced arthritis in mice as a model of RA. (27) Other authors reported elevation of serum TNF-[alpha] in RA patients and our results are consistent with previous findings. (11,28,29)
In our study, there was no correlation between serum TNF-[alpha] concentration and the serum levels of RF, anti-CCP, erythrocyte sedimentation rate, and CRP in RA patients. RF is detectable in nearly 70% of RA patients, although its presence is not specific for RA. (30) Also, anti-CCP assays are detectable in about 70% of patients with RA and are highly specific for RA. (31) CRP is an acute-phase protein mostly synthesized by hepatocytes and Kupffer cells in the liver and is regulated by cytokines such as TNF-[alpha] and IL-6.32 As expected, the concentration of CRP was significantly increased in RA patients as compared to the controls. In contrast to our results, the correlation of TNF-[alpha] level with RF, CRP, and erythrocyte sedimentation rate was reported in RA patients. (33)
We determined -238 G/A polymorphism in the promoter region of the TNF-[alpha] gene in RA patients and healthy controls. Our findings showed that genotype GG in RA (76.6%) and control groups (83.5%) had the highest frequency. The GA genotype frequency was 17.8% in RA group and 8.8% in the control group. The frequency of the AA genotype in both RA and control groups had the lowest frequency. This SNP polymorphism was studied in some disorders in different countries. Zammiti et al. (34) studied association between TNF-[alpha] polymorphism and idiopathic recurrent miscarriage in Tunisia population. The GG genotype frequency was 71.1% in the cases and 81% in the controls and the AA genotype had the lowest frequency in both groups. This polymorphism was surveyed in Turkish RA patients and compared with control subjects. The results showed that the GG genotype frequency was 96% in both case and control groups and the AA genotype was not found in the two groups. (35) The -238 G/A polymorphism in TNF-[alpha] gene was determined in Chinese patients with Graves' disease by Gu et al. (36) where the GG genotype frequency was 95.3% in patients and 89.5% in the controls and the AA genotype was not detectable in the two groups. Also, the frequency of GG genotype was 88.65% in tuberculosis patients and 90.97% in controls in Asian Indians. (37) The association of this polymorphism with Paget's disease of bone was studied in the Spanish population. The results showed that GG genotype in patients (88%) and controls (86%) had the highest frequency. (38) The frequency of genotypes in these studies is consistent with our results but the prevalence of the genotypes is different. The difference in race, sample size, and sampling might explain this discrepancy.
We could not find a significant difference in the genotype frequencies of the -238 G/A polymorphism between the RA and control groups. In a study, researchers investigated TNF-[alpha] -238 polymorphism and association with messenger ribonucleic acid expression and soluble TNF-[alpha] in 50 RA patients and 100 healthy subjects. No significant difference in TNF-[alpha] -238 G/A polymorphism was observed in both groups. (33) Fabris et al. (39) investigated this polymorphism in 100 RA patients with severe and mild disease and 45 healthy blood donors. They reported that AG genotype was absent in severe-unresponsive RA, but present in mild-responsive RA patients and GG homozygosity associated with severity and unresponsiveness. In a prospective study, the correlation between TNF-[alpha] -238G/A promoter polymorphism with joint damage in RA was determined. The results showed that TNF -238 GG genotype contributed to the progression of joint destruction in RA. (40) Association of -238 G/A polymorphism with pathogenesis in some autoimmune diseases was studied. The results of various studies on this topic have been inconsistent. Laddha et al. (41) reported significant association of this SNP with generalized and localized vitiligo. The study performed on Chinese patients with Graves' disease indicated that the distribution of -238 G/A genotypic and allelic frequencies between patient and control subjects was significantly different. The G allele of TNF-[alpha] -238 conferred a higher risk of Graves' disease as compared with A allele. (36) Ferguson et al. (42) studied association of this SNP in the TNF-[alpha] gene with inflammatory bowel disease risk. They did not find a significant difference between controls and Crohn's disease patients, and ulcerative colitis patients and controls. Independent association of TNF-[alpha] polymorphism with type 1 diabetes susceptibility has been reported. (43)
As part of our research, we compared serum TNF-[alpha] level in the different genotypes in RA patients and found that the serum TNF-[alpha] levels were similar in different genotypes. Our result is not compatible with a study conducted on RA patients, which showed that GG genotype was associated with higher serum TNF levels than GA genotype. (33) Also, another study on vitiligo patients showed that patients with GA and AA genotype had a significant increase in serum TNF-[alpha] level as compared to controls. (41)
We found a significant difference between genotypes and DAS28 in RA patients. The AA genotype had the highest DAS28 value. The difference in DAS activity score between genotypes may predict the treatment outcome in RA patients.
There are some limitations to our study, which could affect the results. There were no consideration and analysis of the type of drugs used by the patients. Some drugs can affect the serum TNF-[alpha] level. In addition, one SNP was determined and compared between RA patients and controls. Furthermore, our sample size may not be large enough which may have weakened our ability for a reliable statistical association.
In conclusion, the findings of the present study indicate that -238G/A polymorphism in TNF-[alpha] gene might not be associated with a high risk of RA in Iranian patients and this SNP do not affect the serum level of TNF-[alpha] in RA patients. Further prospective studies on larger sample sizes with different ethnicities are required to confirm our findings. Also, multiple SNPs should be considered in future studies.
Shahid Sadoughi University of Medical Sciences provided a grant for this research project. This manuscript is a part of the M.Sc thesis of Parisa Noorbakhsh. The authors are grateful to Mr. Ali Amini and Mrs. Fatemeh Zare for their technical assistance and Dr. Amin Dehghan for critical reading of the manuscript. We would also like to thank Dr. Mahmood Vakilifor for his assistance in statistical analysis.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.
(1.) McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
(2.) Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
(3.) Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800.
(4.) Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 2009;29:411-5.
(5.) Sandoughi M, Zakeri Z, Tehrani Banihashemi A, Davatchi F, Narouie B, Shikhzadeh A, et al. Prevalence of musculoskeletal disorders in southeastern Iran: a WHO-ILAR COPCORD study (stage 1, urban study). Int J Rheum Dis 2013;16:509-17.
(6.) van der Woude D, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Thomson W, Worthington J, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:916-23.
(7.) Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012;39:222-8.
(8.) Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
(9.) Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.
(10.) Rossol M, Schubert K, Meusch U, Schulz A, Biedermann B, Grosche J, et al. Tumor necrosis factor receptor type I expression of CD4+ T cells in rheumatoid arthritis enables them to follow tumor necrosis factor gradients into the rheumatoid synovium. Arthritis Rheum 2013;65:1468-76.
(11.) Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol 2001;28:1211-7.
(12.) Maury CP, Liljestrom M, Laiho K, Tiitinen S, Kaarela K, Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068-76.
(13.) Hajeer AH, Dababneh A, Makki RF, Thomson W, Poulton K, Gonzalez-Gay MA, et al. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens 2000;55:319-25.
(14.) Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17:3532-8.
(15.) Gu L, Su L, Wu G, Chen Q, Yan Y, Xie J, Tan J, Liang B, Tang N. Association between TNF-[alpha] 238G/A polymorphisms and the risk of ischemic stroke. Int J Neurosci 2013;123:1-6.
(16.) Zhang Z, Zhu H, Pu X, Meng S, Zhang F, Xun L, et al. Association between tumor necrosis factor alpha-238G/a polymorphism and tuberculosis susceptibility: a meta-analysis study. BMC Infect Dis 2012;12:328.
(17.) Zhang B, Liu T, Wang Z. Association of tumor necrosis factor-a gene promoter polymorphisms (-308G/A, -238G/A) with recurrent spontaneous abortion: a meta-analysis. Hum Immunol 2012;73:574-9.
(18.) Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
(19.) Ozen S, Alikasifoglu M, Bakkaloglu A, Duzova A, Jarosova K, Nemcova D, et al. Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatology (Oxford) 2002;41:223-7.
(20.) Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000;50:216-28.
(21.) Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000;1:185-90.
(22.) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
(23.) McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
(24.) Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996;16:459-67.
(25.) Tsytsykova AV, Goldfeld AE. Inducer-specific enhanceosome formation controls tumor necrosis factor alpha gene expression in T lymphocytes. Mol Cell Biol 2002;22:2620-31.
(26.) Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
(27.) Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 2007;361:265-84.
(28.) Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 2006;25:448-52.
(29.) Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol (Madr) 2015;43:81-7.
(30.) Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.
(31.) Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
(32.) Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
(33.) Oregon-Romero E, Vazquez-Del Mercado M, Ruiz-Quezada SL, Navarro-Hernandez RE, RangelVillalobos H, Martinez-Bonilla G, et al. Tumor necrosis factor alpha-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha. J Investig Med 2008;56:937-43.
(34.) Zammiti W, Mtiraoui N, Khairi H, Gris JC, Almawi WY, Mahjoub T. Associations between tumor necrosis factor-alpha and lymphotoxin-alpha polymorphisms and idiopathic recurrent miscarriage. Reproduction 2008;135:397-403.
(35.) Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin Rheumatol 2008;27:1243-8.
(36.) Gu LQ, Zhu W, Pan CM, Zhao L, Zhang MJ, Liu JM, et al. Tumor necrosis factor alpha (TNF-alpha) polymorphisms in Chinese patients with Graves' disease. Clin Biochem 2010;43:223-7.
(37.) Sharma S, Rathored J, Ghosh B, Sharma SK. Genetic polymorphisms in TNF genes and tuberculosis in North Indians. BMC Infect Dis 2010;10:165.
(38.) Corral-Gudino L, del Pino-Montes J, Garcia-Aparicio J, Alonso-Garrido M, Gonzalez-Sarmiento R. Paget's disease of bone is not associated with common polymorphisms in interleukin-6, interleukin-8 and tumor necrosis factor alpha genes. Cytokine 2010;52:146-50.
(39.) Fabris M, Di Poi E, D'Elia A, Damante G, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002;29:29-33.
(40.) Kaijzel EL, van Krugten MV, Brinkman BM, Huizinga TW, van der Straaten T, Hazes JM, et al. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4:724-33.
(41.) Laddha NC, Dwivedi M, Begum R. Increased Tumor Necrosis Factor (TNF)-a and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One 2012 20;7:e52298.
(42.) Ferguson LR, Huebner C, Petermann I, Gearry RB, Barclay ML, Demmers P, et al. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol 2008;14:4652-61.
(43.) Shin HD, Yang SW, Kim DH, Park Y. Independent association of tumor necrosis factor polymorphism with type 1 diabetes susceptibility. Ann N Y Acad Sci 2008;1150:76-85.
Hossein HADINEDOUSHAN,  Parisa NOORBAKHSH,  Hossein SOLEYMANI-SALEHABADI 
 Department of Immunology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
 Department of Rheumatology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Received: January 18, 2016 Accepted: April 19, 2016 Published online: July 27, 2016
Correspondence: Parisa Noorbakhsh, MD. Department of Immunology, Shahid Sadoughi University of Medical Sciences, 8916188635 Yazd, Iran. Tel: +98 353 62 85 40 56 e-mail: firstname.lastname@example.org
Caption: Figure 1. Gel picture showing polymerase chain reaction product for -238 G'A (rs361525). The polymerase chain reaction product size was 315 bp.
Table 1. Main demographic and clinical characteristics of rheumatoid factor patients and controls RA patients (n = 90) % Mean [+ or -] SD Range Gender Female 77.8 Male 22.2 Age (year) 50.3 [+ or -] 9.1 26-65 Age at diagnosis (year) 43.8 [+ or -] 10.2 Duration of the disease 5.1 [+ or -] 2.93 (year) Disease Activity Score 28 3.6 [+ or -] 0.8 Hemoglobin levels (g/dL) 12.94 [+ or -] 1.31 Erythrocyte sedimentation 28.48 [+ or -] 19.23 rate Rheumatoid factor (Iu/mL) 15.42 [+ or -] 8.69 C-reactive protein (mg/dL) 17.847 [+ or -] 11.48 Anti-cyclic citrullinated 189.57 [+ or -] 127.96 peptide (U/mL) Controls (n = 90) % Mean [+ or -] SD Range Gender Female 76.6 Male 23.4 Age (year) 48.6 [+ or -] 12.4 27-63 Age at diagnosis (year) -- Duration of the disease -- (year) Disease Activity Score 28 -- Hemoglobin levels (g/dL) -- Erythrocyte sedimentation -- rate Rheumatoid factor (Iu/mL) 9.11 [+ or -] 2.33 C-reactive protein (mg/dL) 4.05 [+ or -] 2.04 Anti-cyclic citrullinated -- peptide (U/mL) RA: Rheumatoid factor; SD: Standard deviation. Table 2. Frequencies of tumor necrosis factor-alpha genotypes and alleles in rheumatoid arthritis patients and control group SNP Allele frequency Genotype frequency rs361525G/A G Allele A Allele GG n % n % n % Rheumatoid arthritis 154 85.5 * 26 14.5 69 76.6 * patients Control group 158 87.8 22 12.2 75 83.5 SNP Genotype frequency rs361525G/A GA AA n % n % Rheumatoid arthritis 16 17.8 5 5.6 patients Control group 8 8.8 7 7.7 SNP: Single nucleotide polymorphisms; * p=0.1; ** p = 0.07.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||ORIGINAL ARTICLE|
|Author:||Hadinedoushan, Hossein; Noorbakhsh, Parisa; Soleymani-Salehabadi, Hossein|
|Publication:||Archives of Rheumatology|
|Date:||Dec 1, 2016|
|Previous Article:||A new explanation of inflammation in rheumatoid arthritis patients with respect to claudin-5, matrix metalloproteinase-9, and neuroserpin.|
|Next Article:||Effects of exercise on low density lipoprotein receptor related protein 5 gene expression in patients with postmenopausal osteoporosis.|